Brief: Erasca Gets FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801

Erasca

22/06/2023 22:05

June 22 (Reuters) - Erasca Inc  ERAS.O :
    * ERASCA GRANTED FDA ORPHAN DRUG DESIGNATION FOR
CNS-PENETRANT
EGFR INHIBITOR ERAS-801 FOR THE TREATMENT OF MALIGNANT GLIOMA
    * ERASCA INC - INITIAL THUNDERBBOLT-1 PHASE 1 MONOTHERAPY
DATA IN
PATIENTS WITH RECURRENT GBM EXPECTED IN H2 2023

Source text for Eikon:  ID:nGNX1HrvLX 
Further company coverage:  ERAS.O 

 ((Reuters.Briefs@thomsonreuters.com;))